Challenges with Endoscopic Therapy for Barrett’s Esophagus - 27/05/15
, Prateek Sharma, MD bRésumé |
Barrett’s esophagus is the only identifiable premalignant condition for esophageal adenocarcinoma. Endoscopic eradication therapy (EET) has revolutionized the management of Barrett’s-related dysplasia and intramucosal cancer. The primary goal of EET is to prevent progression to invasive esophageal adenocarcinoma and ultimately improve survival rates. There are several challenges with EET that can be encountered before, during, or after the procedure that are important to understand to optimize the effectiveness and safety of EET and ultimately improve patient outcomes. This article focuses on the challenges with EET and discusses them under the categories of preprocedural, intraprocedural, and postprocedural challenges.
Le texte complet de cet article est disponible en PDF.Keywords : Barrett’s esophagus, Esophageal adenocarcinoma, Endoscopic eradication therapy, Endoscopic mucosal resection, Radiofrequency ablation
Plan
| Disclosures: S. Wani was supported by the American Gastroenterological Association Takeda Research Scholar Award in GERD and Barrett’s esophagus and University of Colorado Department of Medicine Early Scholars Award. He received grant support from Cook Medical. He is a consultant for Covidien. P. Sharma received grant support from Barrx Medical, CDX Labs, Cook Medical, Ninepoint Medical, and Olympus Inc. |
Vol 44 - N° 2
P. 355-372 - juin 2015 Retour au numéro
Article précédent
- Ablative Endoscopic Therapies for Barrett’s-Esophagus-Related Neoplasia
- Shajan Peter, Klaus Mönkemüller
- Biomarkers in Barrett’s Esophagus : Role in Diagnosis, Risk Stratification, and Prediction of Response to Therapy
- Ajay Bansal, Rebecca C. Fitzgerald
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?